A detailed history of Eqis Capital Management, Inc. transactions in Ginkgo Bioworks Holdings, Inc. stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 236,564 shares of DNA stock, worth $1.97 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
236,564
Previous 101,725 132.55%
Holding current value
$1.97 Million
Previous $118,000 33.9%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.28 - $1.16 $37,754 - $156,413
134,839 Added 132.55%
236,564 $78,000
Q1 2024

May 14, 2024

SELL
$1.06 - $1.67 $8,323 - $13,112
-7,852 Reduced 7.17%
101,725 $118,000
Q4 2023

Feb 14, 2024

BUY
$1.26 - $1.79 $87,343 - $124,082
69,320 Added 172.19%
109,577 $185,000
Q3 2023

Nov 13, 2023

BUY
$1.61 - $2.54 $15,167 - $23,929
9,421 Added 30.55%
40,257 $72,000
Q2 2023

Aug 14, 2023

BUY
$1.14 - $1.95 $35,153 - $60,130
30,836 New
30,836 $57,000

Others Institutions Holding DNA

About Ginkgo Bioworks Holdings, Inc.


  • Ticker DNA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,287,779,968
  • Market Cap $10.7B
  • Description
  • Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...
More about DNA
Track This Portfolio

Track Eqis Capital Management, Inc. Portfolio

Follow Eqis Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.